StockNews.com Begins Coverage on Minerva Neurosciences (NASDAQ:NERV)

Equities researchers at StockNews.com began coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report issued on Saturday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating and issued a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, November 6th.

Minerva Neurosciences Stock Performance

Shares of Minerva Neurosciences stock opened at $1.82 on Friday. The stock has a market capitalization of $12.73 million, a PE ratio of -4.14 and a beta of 0.12. Minerva Neurosciences has a 52 week low of $1.77 and a 52 week high of $9.40. The stock has a 50 day moving average price of $2.18 and a two-hundred day moving average price of $2.41.

Institutional Investors Weigh In On Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Citadel Advisors LLC grew its stake in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 25,764 shares of the biopharmaceutical company’s stock after purchasing an additional 8,525 shares during the period. Citadel Advisors LLC owned about 0.37% of Minerva Neurosciences worth $57,000 as of its most recent filing with the SEC. 34.56% of the stock is currently owned by institutional investors and hedge funds.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.